Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

Com­pass Path­ways is push­ing back the time­lines of two key piv­otal read­outs, de­lay­ing da­ta for a psilo­cy­bin pro­gram that’s one of the lead­ers in psy­che­del­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER